Requirement for B cell-derived immunoglobulin for TH activation by the type 2 antigen polyvinylpyrrolidone

Helen Braley-mullen, Gregg Milligan, Anne M. Van Buskirk

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Th specific for the type 2 antigen potyvlnylpyrrolldone (PVP) could not be activated in vivo or in vitro In mice rendered B cell deficient by treatment from birth with antl-lgM. The requirement for B cells was apparently not due to a requirement for B cells to function as antigen presenting cells for Th activation since T cells also were not activated when antl-lgM treated mice were reconstituted with B cells prior to priming with PVP. In addition, removal of B cells from spleens of adult of adult mice had no effect on the ability of PVP to activate Th in vitro. Potential nonspecific effects of chronic antl-lgM treatment on T cell function are unlikely since T cells from antl-lgM treated mice provided help to B cells for antibody responses to horse red blood cells responded normally to T cell mltogens and had a CD4:CD8 ratio like that of untreated mice; PVP primed T cells from anti-IgM treated mice also did not actively suppress the helper activity of PVP primed T cells from normal mice. In addition, PVP-speclflc Th were able to be activated in mice given multiple injections of antl-lgM beginning 2 weeks after birth and in mice given MOPC 104E IgM together with antl-lgM; under these conditions B cell depletion by the anti-IgM did not occur. Thus activation of PVP-speclflc Th requires that B cells be present during the first few weeks after birth. Experiments in which mice were given injections of normal mice Ig together with the antl-lgM indicate that the function of B cells for Th activation in this system can be replaced by B cell-derived Ig. Thus PVP-speclfic Th could be activated in mice treated from birth with antl-lgM plus normal Ig despite the absence of significant numbers of B cells in the spleens of these mice.

Original languageEnglish (US)
Pages (from-to)805-815
Number of pages11
JournalInternational Immunology
Volume6
Issue number6
DOIs
StatePublished - Jun 1994
Externally publishedYes

Fingerprint

Povidone
Immunoglobulin
B Cells
Antigens
Immunoglobulins
Mouse
Activation
B-Lymphocytes
Chemical activation
Cells
T-cells
Requirements
T-Lymphocytes
Parturition
Injection
Spleen
T Cell Activation
CD4-CD8 Ratio
Injections
Red Blood Cells

Keywords

  • Anti-IgM treatment
  • B cell depletion

ASJC Scopus subject areas

  • Statistics, Probability and Uncertainty
  • Applied Mathematics
  • Public Health, Environmental and Occupational Health
  • Neuropsychology and Physiological Psychology
  • Transplantation
  • Immunology

Cite this

Requirement for B cell-derived immunoglobulin for TH activation by the type 2 antigen polyvinylpyrrolidone. / Braley-mullen, Helen; Milligan, Gregg; Van Buskirk, Anne M.

In: International Immunology, Vol. 6, No. 6, 06.1994, p. 805-815.

Research output: Contribution to journalArticle

@article{1d2627b1dd674c1292491a65b1fe4e09,
title = "Requirement for B cell-derived immunoglobulin for TH activation by the type 2 antigen polyvinylpyrrolidone",
abstract = "Th specific for the type 2 antigen potyvlnylpyrrolldone (PVP) could not be activated in vivo or in vitro In mice rendered B cell deficient by treatment from birth with antl-lgM. The requirement for B cells was apparently not due to a requirement for B cells to function as antigen presenting cells for Th activation since T cells also were not activated when antl-lgM treated mice were reconstituted with B cells prior to priming with PVP. In addition, removal of B cells from spleens of adult of adult mice had no effect on the ability of PVP to activate Th in vitro. Potential nonspecific effects of chronic antl-lgM treatment on T cell function are unlikely since T cells from antl-lgM treated mice provided help to B cells for antibody responses to horse red blood cells responded normally to T cell mltogens and had a CD4:CD8 ratio like that of untreated mice; PVP primed T cells from anti-IgM treated mice also did not actively suppress the helper activity of PVP primed T cells from normal mice. In addition, PVP-speclflc Th were able to be activated in mice given multiple injections of antl-lgM beginning 2 weeks after birth and in mice given MOPC 104E IgM together with antl-lgM; under these conditions B cell depletion by the anti-IgM did not occur. Thus activation of PVP-speclflc Th requires that B cells be present during the first few weeks after birth. Experiments in which mice were given injections of normal mice Ig together with the antl-lgM indicate that the function of B cells for Th activation in this system can be replaced by B cell-derived Ig. Thus PVP-speclfic Th could be activated in mice treated from birth with antl-lgM plus normal Ig despite the absence of significant numbers of B cells in the spleens of these mice.",
keywords = "Anti-IgM treatment, B cell depletion",
author = "Helen Braley-mullen and Gregg Milligan and {Van Buskirk}, {Anne M.}",
year = "1994",
month = "6",
doi = "10.1093/intimm/6.6.805",
language = "English (US)",
volume = "6",
pages = "805--815",
journal = "International Immunology",
issn = "0953-8178",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - Requirement for B cell-derived immunoglobulin for TH activation by the type 2 antigen polyvinylpyrrolidone

AU - Braley-mullen, Helen

AU - Milligan, Gregg

AU - Van Buskirk, Anne M.

PY - 1994/6

Y1 - 1994/6

N2 - Th specific for the type 2 antigen potyvlnylpyrrolldone (PVP) could not be activated in vivo or in vitro In mice rendered B cell deficient by treatment from birth with antl-lgM. The requirement for B cells was apparently not due to a requirement for B cells to function as antigen presenting cells for Th activation since T cells also were not activated when antl-lgM treated mice were reconstituted with B cells prior to priming with PVP. In addition, removal of B cells from spleens of adult of adult mice had no effect on the ability of PVP to activate Th in vitro. Potential nonspecific effects of chronic antl-lgM treatment on T cell function are unlikely since T cells from antl-lgM treated mice provided help to B cells for antibody responses to horse red blood cells responded normally to T cell mltogens and had a CD4:CD8 ratio like that of untreated mice; PVP primed T cells from anti-IgM treated mice also did not actively suppress the helper activity of PVP primed T cells from normal mice. In addition, PVP-speclflc Th were able to be activated in mice given multiple injections of antl-lgM beginning 2 weeks after birth and in mice given MOPC 104E IgM together with antl-lgM; under these conditions B cell depletion by the anti-IgM did not occur. Thus activation of PVP-speclflc Th requires that B cells be present during the first few weeks after birth. Experiments in which mice were given injections of normal mice Ig together with the antl-lgM indicate that the function of B cells for Th activation in this system can be replaced by B cell-derived Ig. Thus PVP-speclfic Th could be activated in mice treated from birth with antl-lgM plus normal Ig despite the absence of significant numbers of B cells in the spleens of these mice.

AB - Th specific for the type 2 antigen potyvlnylpyrrolldone (PVP) could not be activated in vivo or in vitro In mice rendered B cell deficient by treatment from birth with antl-lgM. The requirement for B cells was apparently not due to a requirement for B cells to function as antigen presenting cells for Th activation since T cells also were not activated when antl-lgM treated mice were reconstituted with B cells prior to priming with PVP. In addition, removal of B cells from spleens of adult of adult mice had no effect on the ability of PVP to activate Th in vitro. Potential nonspecific effects of chronic antl-lgM treatment on T cell function are unlikely since T cells from antl-lgM treated mice provided help to B cells for antibody responses to horse red blood cells responded normally to T cell mltogens and had a CD4:CD8 ratio like that of untreated mice; PVP primed T cells from anti-IgM treated mice also did not actively suppress the helper activity of PVP primed T cells from normal mice. In addition, PVP-speclflc Th were able to be activated in mice given multiple injections of antl-lgM beginning 2 weeks after birth and in mice given MOPC 104E IgM together with antl-lgM; under these conditions B cell depletion by the anti-IgM did not occur. Thus activation of PVP-speclflc Th requires that B cells be present during the first few weeks after birth. Experiments in which mice were given injections of normal mice Ig together with the antl-lgM indicate that the function of B cells for Th activation in this system can be replaced by B cell-derived Ig. Thus PVP-speclfic Th could be activated in mice treated from birth with antl-lgM plus normal Ig despite the absence of significant numbers of B cells in the spleens of these mice.

KW - Anti-IgM treatment

KW - B cell depletion

UR - http://www.scopus.com/inward/record.url?scp=0028287742&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028287742&partnerID=8YFLogxK

U2 - 10.1093/intimm/6.6.805

DO - 10.1093/intimm/6.6.805

M3 - Article

VL - 6

SP - 805

EP - 815

JO - International Immunology

JF - International Immunology

SN - 0953-8178

IS - 6

ER -